Special Drug Use-results Survey for long-term use of Doxil injection 20mg (ovarian cancer aggravated after chemotherapy)

Special Drug Use-results Survey for long-term use of Doxil injection 20mg (ovarian cancer aggravated after chemotherapy) - Special Drug Use-results Survey for long-term use of Doxil injection 20mg (ovarian cancer aggravated after chemotherapy)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015902

Enrollment

500

Registered

2014-12-15

Start date

2009-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer aggravated after chemotherapy

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All patients who were treated with Doxil injection 20mg

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction) Effectiveness(Antitumor efficacy)	—

Countries

Japan

Contacts

Public ContactTomohiko Shigemasa

Janssen Pharmaceutical K.K. Safety Risk Management Dept.

tshigema@its.jnj.com03-4411-5874

Outcome results